C86.51
Angioimmunoblastic T-cell lymphoma, in remission
Clinical Classification Guidelines
Inclusion Terms
- Angioimmunoblastic lymphadenopathy with dysproteinemia (AILD), in remission
Medical Intelligence & Overview
Angioimmunoblastic T-cell lymphoma (AITL) is a rare type of blood cancer that originates in the lymphatic system. When someone is described as being 'in remission,' it means that the signs and symptoms of the disease are no longer present, and the disease activity has decreased significantly following treatment. Specifically, the ICD-10 code C86.51 refers to AITL that is currently in a state of remission, indicating a positive response to therapy and a reduction in the disease's activity.
Causes & Symptoms
Clinical Causes: Genetic mutations affecting T-cells, which are a type of immune cell Potential links to viruses, such as Epstein-Barr virus (EBV) and Human T-cell leukemia virus (HTLV) Unknown exact triggers, as the development of this lymphoma involves complex interactions within the immune system
Key Symptoms: Swollen lymph nodes, often painless, in areas like the neck, armpits, or groin Unexplained fever or night sweats Unintentional weight loss Fatigue or weakness Skin rashes or skin abnormalities Abdominal discomfort or swelling Breathing difficulties if lymph nodes enlarge in the chest area Itching or skin changes
Diagnostic & Treatment
Diagnosis Path: Physical examination to check for swollen lymph nodes or other abnormalities Biopsy of affected lymph nodes or tissues to identify cancerous T-cells Imaging tests such as CT scans or PET scans to determine the extent of the disease Blood tests to assess overall health and detect any abnormal blood cell counts or immune activity Bone marrow biopsy in some cases to evaluate spread to the bone marrow
Treatment Protocols: Chemotherapy regimens to target and destroy cancerous T-cells Immunotherapy to boost the immune system's ability to fight residual cancer cells Targeted therapy with agents designed specifically to attack abnormal cancer cells Radiation therapy in select cases, especially if localized disease persists Follow-up care involving regular scans and blood tests to detect early signs of recurrence
Clinical Advice & FAQs
Billing Guidance
Is C86.51 a billable ICD-10 code?
Yes, C86.51 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report C86.51?
Clinical documentation must specify the nature of Angioimmunoblastic T-cell lymphoma, in remission and any associated comorbidities for accurate reporting.
Cite this Clinical Reference